Heparin for Treating Sepsis: The HETRASE Study
Author Information
Author(s): Jaimes Fabián, De La Rosa Gisela, Arango Clara, Fortich Fernando, Morales Carlos, Aguirre Daniel, Patiño Pablo
Primary Institution: Universidad de Antioquia
Hypothesis
Can low-dose continuous infusion of unfractioned heparin improve outcomes in patients with sepsis?
Conclusion
The study aims to rigorously test the efficacy of heparin in sepsis treatment, potentially providing important data on its effects on mortality and organ dysfunction.
Supporting Evidence
- Sepsis is a leading cause of death worldwide with a high mortality rate.
- Previous treatments for sepsis have shown limited success.
- Heparin may have additional benefits beyond its anticoagulant properties.
Takeaway
This study is testing if giving a medicine called heparin can help people who are very sick from infections called sepsis.
Methodology
Randomized, double-masked, placebo-controlled, single-center clinical trial.
Potential Biases
Potential biases may arise from the single-center design and the randomization process.
Limitations
The study may not be generalizable to all sepsis patients due to specific inclusion and exclusion criteria.
Participant Demographics
Patients aged 18 years or older, hospitalized with clinically or microbiologically confirmed sepsis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website